These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35284050)

  • 1. Understanding the influence of AMG 510 on the structure of KRAS
    Li Y; Han L; Zhang Z
    Comput Struct Biotechnol J; 2022; 20():1056-1067. PubMed ID: 35284050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations.
    Pantsar T
    Sci Rep; 2020 Jul; 10(1):11992. PubMed ID: 32686745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
    Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
    Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Tu G; Liu Q; Qiu Y; Leung EL; Yao X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.
    Huynh MV; Parsonage D; Forshaw TE; Chirasani VR; Hobbs GA; Wu H; Lee J; Furdui CM; Poole LB; Campbell SL
    J Biol Chem; 2022 Aug; 298(8):102186. PubMed ID: 35753348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
    Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
    Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research.
    Wu LL; Jiang WM; Liu ZY; Zhang YY; Qian JY; Liu Y; Huang YY; Li K; Li ZX; Ma GW; Xie D
    Discov Oncol; 2023 Jun; 14(1):91. PubMed ID: 37284902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
    Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
    J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
    Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
    Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
    ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Breakthrough Brought about by Targeting KRAS
    Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS
    Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y
    Front Oncol; 2022; 12():915512. PubMed ID: 36033504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
    Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
    Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on Sotorasib (AMG 510) for
    Zhang SS; Nagasaka M
    Lung Cancer (Auckl); 2021; 12():115-122. PubMed ID: 34675734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.